CD19 and exocrine pancreatic carcinoma: On the other hand, we observed increased anti-tumor potential due to the implementation of the AW promoter against an artificial CD19+ model of pancreatic carcinoma in vitro, which confirms the potential benefits of this TCR-like promoter in a different context.